Adicet Bio(US:ACET)2025-03-06 21:02Financial Performance - Net loss for Q4 2024 was $28.7 million, or $0.32 per share, compared to a net loss of $29.5 million, or $0.69 per share in Q4 2023[10] - The net loss for the full year 2024 was $117.1 million, or $1.33 per share, compared to a net loss of $142.7 million, or $3.31 per share in 2023[10] Research and Development Expenses - R&D expenses for Q4 2024 were $23.3 million, a decrease of 6.0% from $24.8 million in Q4 2023[10] - For the full year 2024, R&D expenses totaled $99.3 million, down from $106.0 million in 2023, a decrease of 6.3%[10] General and Administrative Expenses - G&A expenses for Q4 2024 were $7.5 million, an increase of 9.7% from $6.8 million in Q4 2023[10] - Full year 2024 G&A expenses were $28.3 million, an increase of 6.8% from $26.5 million in 2023[10] Cash Position - Total cash, cash equivalents, and short-term investments were $176.3 million as of December 31, 2024, up from $159.7 million as of December 31, 2023[10] Clinical Trials and Designations - The company expects to report preliminary clinical data from the ADI-001 trial in lupus nephritis in 1H25 and additional data in 2H25[2] - Patient enrollment for ADI-001 in systemic lupus erythematosus and other autoimmune diseases is expected to begin in 2Q25[2] - Adicet received FDA Fast Track Designation for ADI-001 for treating refractory systemic lupus erythematosus and systemic sclerosis in February 2025[6]